SCHEMBL7654348

SCHEMBL7654348

CC[C@H](O)c1cccc(N)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CPN1 P15169 1/20 0.47
CPB2 Q96IY4 1/20 0.47
CYP3A4 P08684 5/20 0.44
CASP1 P29466 1/20 0.44
RECQL P46063 1/20 0.44
HIF1A Q16665 3/20 0.43
GALR3 O60755 1/20 0.43
TP53 P04637 1/20 0.42
ADRB2 P07550 5/20 0.42
SLC6A3 Q01959 4/20 0.42
ADRB1 P08588 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRB3 P13945 1/20 0.42
TSHR P16473 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
NFKB1 P19838 1/20 0.42
DRD1 P21728 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466349 1.00 LMNA (0.59) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL5466344 1.00 LMNA (0.59) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL11595350 0.87 LMNA (0.70) LMNAHIF1AGALR3ADRB2SLC6A3
SCHEMBL9158456 0.84 CPN1 (0.45) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL15178195 0.84 CPN1 (0.45) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL9158459 0.84 CPN1 (0.45) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL6257483 0.82 TSHR (0.45) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL10635780 0.81 TSHR (0.47) LMNACPN1CPB2CYP3A4RECQL
SCHEMBL20032392 0.81 CYP3A4 (0.46) LMNACPN1CPB2CYP3A4CASP1
SCHEMBL2238144 0.81 CPN1 (0.49) LMNACPN1CPB2CYP3A4CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020143043-A1 Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-10-03 US disclosed
CN-1054418-A For with relate to (S)-go improvement of first fluoxetine LILLY CO ELI (US) 1991-09-11 CN disclosed
CN-1042704-A FLUOXETINE ANALOG LILLY CO ELI (US) 1990-06-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143043-A1 Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them VCAM1, ITGA1, ITGA4 LMNA 1503/4885CPN1 4861/4885CPB2 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.